Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $432.01 | 9 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ShockWave Medical, Inc | $172.86 | 1 | $0 (2024) |
| Allergan Inc. | $97.33 | 1 | $0 (2019) |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $43.86 | 1 | $0 (2018) |
| Amgen Inc. | $24.28 | 1 | $0 (2017) |
| ABBVIE INC. | $20.84 | 1 | $0 (2022) |
| LEO Pharma Inc. | $20.73 | 1 | $0 (2017) |
| Arcutis Biotherapeutics, Inc. | $20.67 | 1 | $0 (2023) |
| Sun Pharmaceutical Industries Inc. | $17.04 | 1 | $0 (2022) |
| Incyte Corporation | $14.40 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $172.86 | 1 | ShockWave Medical, Inc ($172.86) |
| 2023 | $20.67 | 1 | Arcutis Biotherapeutics, Inc. ($20.67) |
| 2022 | $52.28 | 3 | ABBVIE INC. ($20.84) |
| 2019 | $97.33 | 1 | Allergan Inc. ($97.33) |
| 2018 | $43.86 | 1 | Ortho Dermatologics, a division of Bausch Health US, LLC ($43.86) |
| 2017 | $45.01 | 2 | Amgen Inc. ($24.28) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/22/2024 | ShockWave Medical, Inc | Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter (Device) | Food and Beverage | In-kind items and services | $172.86 | General |
| Category: Lithoplasty | ||||||
| 02/18/2023 | Arcutis Biotherapeutics, Inc. | — | Food and Beverage | In-kind items and services | $20.67 | General |
| 07/15/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $20.84 | General |
| Category: IMMUNOLOGY | ||||||
| 03/18/2022 | Sun Pharmaceutical Industries Inc. | Winlevi (Drug), Absorica LD | Food and Beverage | In-kind items and services | $17.04 | General |
| Category: Dermatology | ||||||
| 02/04/2022 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $14.40 | General |
| Category: Dermatology | ||||||
| 03/02/2019 | Allergan Inc. | BOTOX COSMETIC | Food and Beverage | In-kind items and services | $97.33 | General |
| 04/09/2018 | Ortho Dermatologics, a division of Bausch Health US, LLC | SILIQ (Drug) | Food and Beverage | In-kind items and services | $43.86 | General |
| Category: DERMATOLOGY | ||||||
| 11/15/2017 | LEO Pharma Inc. | ENSTILAR (Drug) | Food and Beverage | In-kind items and services | $20.73 | General |
| Category: DERMATOLOGY | ||||||
| 03/05/2017 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $24.28 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 364 | 678 | $62,053 | $18,324 |
| 2022 | 6 | 353 | 739 | $65,497 | $21,912 |
| 2021 | 7 | 263 | 497 | $49,927 | $16,266 |
| 2020 | 8 | 403 | 693 | $70,935 | $24,478 |
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 90 | 95 | $14,166 | $4,872 | 34.4% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 49 | 51 | $11,355 | $4,193 | 36.9% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 90 | 101 | $13,296 | $3,262 | 24.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 39 | 40 | $8,737 | $2,641 | 30.2% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 28 | 28 | $5,600 | $1,787 | 31.9% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 68 | 363 | $8,900 | $1,569 | 17.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 84 | 92 | $13,719 | $5,731 | 41.8% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 57 | 64 | $14,249 | $5,593 | 39.3% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 79 | 92 | $12,111 | $3,189 | 26.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 36 | 39 | $8,518 | $3,152 | 37.0% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 31 | 32 | $6,400 | $2,140 | 33.4% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 66 | 420 | $10,500 | $2,107 | 20.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 60 | 62 | $9,245 | $3,683 | 39.8% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 39 | 43 | $9,574 | $3,608 | 37.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 33 | 39 | $8,518 | $2,766 | 32.5% |
| 17000 | Destruction of skin growth | Office | 2021 | 53 | 63 | $8,293 | $2,189 | 26.4% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 24 | 26 | $5,200 | $1,829 | 35.2% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 41 | 251 | $6,275 | $1,165 | 18.6% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 13 | 13 | $2,821 | $1,026 | 36.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 109 | 109 | $23,808 | $9,090 | 38.2% |
| 17110 | Destruction of up to 14 skin growths | Office | 2020 | 48 | 49 | $10,909 | $4,443 | 40.7% |
| 17000 | Destruction of skin growth | Office | 2020 | 91 | 92 | $12,111 | $3,676 | 30.3% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2020 | 32 | 32 | $6,400 | $2,031 | 31.7% |
| 17003 | Destruction of 2-14 skin growths | Office | 2020 | 72 | 358 | $8,950 | $1,744 | 19.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 27 | 27 | $4,026 | $1,571 | 39.0% |
About Dr. Charles Sola, M.D
Dr. Charles Sola, M.D is a Dermatology healthcare provider based in Jacksonville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/19/2008. The National Provider Identifier (NPI) number assigned to this provider is 1487815858.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Charles Sola, M.D has received a total of $432.01 in payments from pharmaceutical and medical device companies, with $172.86 received in 2024. These payments were reported across 9 transactions from 9 companies. The most common payment nature is "Food and Beverage" ($432.01).
As a Medicare-enrolled provider, Sola has provided services to 1,383 Medicare beneficiaries, totaling 2,607 services with total Medicare billing of $80,980. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Practice Information
- Specialty Dermatology
- Location Jacksonville, FL
- Active Since 06/19/2008
- Last Updated 10/03/2023
- Taxonomy Code 207N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1487815858
Products in Payments
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter (Device) $172.86
- SILIQ (Drug) $43.86
- SKYRIZI (Biological) $20.84
- ENSTILAR (Drug) $20.73
- Winlevi (Drug) $17.04
- OPZELURA (Drug) $14.40
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Jacksonville
Dr. Pearl Kwong, Md Phd, MD PHD
Dermatology — Payments: $2.8M
Michael Bernhardt, Md, MD
Dermatology — Payments: $702,961
Kristen Stewart, M.d, M.D
Dermatology — Payments: $107,300
Jason Sluzevich, Md, MD
Dermatology — Payments: $61,523
Dr. Douglas Robins, Md, MD
Dermatology — Payments: $24,873
Jean Mcclintock, Md, MD
Dermatology — Payments: $14,036